A Phase 4 interventional study of Amlodipine besylate/atorvastatin calcium single pill combination in Hypertension and Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 126 sites in 20 countries. Open to participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Hypertension by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Hypertension · Viatris Inc..
Among the 34 studies in Hypertension by Viatris Inc., this one is the 2nd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 4, and was the 21st registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 34 studies in Hypertension by Viatris Inc. is open now. The open studies under Hypertension, anywhere →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 35 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,531 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 330 across the 27 interventional studies, 3,338 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Hypertension by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open label caduet added to usual care regimen followed by investigators.
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).
Time frame: Baseline, Month 12
Framingham 10-year Risk of Total CHD at Month 4
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).
Time frame: Baseline, Month 4
European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).
Time frame: Baseline, Month 12
European SCORE 10-year Risk of Fatal CVD at Month 4
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).
Time frame: Baseline, Month 4
Framingham 10-year Risk of Stroke at Month 12
Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).
Time frame: Baseline, Month 12
Framingham 10-year Risk of Stroke at Month 4
Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).
Time frame: Baseline, Month 4
Change From Baseline in Framingham 10-year Risk of Developing Total CHD
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.
Time frame: Baseline, Month 4, Month 12
Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.
Time frame: Baseline, Month 4, Month 12
Mean Systolic and Diastolic Blood Pressure at Month 4
Time frame: Month 4
Mean Systolic and Diastolic Blood Pressure at Month 12
Time frame: Month 12
Change From Baseline in Systolic Blood Pressure (SBP) at Month 4
Time frame: Baseline, Month 4
Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4
Time frame: Baseline, Month 4
Change From Baseline in SBP at Month 12
Time frame: Baseline, Month 12
Change From Baseline in DBP at Month 12
Time frame: Baseline, Month 12
Mean Lipid Parameters at Month 4
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
Time frame: Month 4
Mean Lipid Parameters at Month 12
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
Time frame: Month 12
Change From Baseline in Lipid Parameters at Month 4
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.
Time frame: Baseline, Month 4
Change From Baseline in Lipid Parameters at Month 12
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
Time frame: Baseline, Month 12
Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months
Goals set at \<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \<140/90 mm Hg or \<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.
Time frame: Month 4, Month 12
Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months
Goal set at \<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \<80 mg/dL according to the European (EU) Society of Cardiology guidelines.
Time frame: Month 4, Month 12
Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months
Treatments indicative of prescribed medications other than study provided Caduet.
Time frame: Month 4, Month 12
Number of Participants With Increase of Treatment Dosages After 4 Months.
Treatments indicative of prescribed medications other than study provided Caduet.
Time frame: Month 4
This was a cluster randomized study: the unit of randomization was the investigator, ie, participants were screened before the investigator was randomized. A total of 136 sites were cluster randomized.
| Milestone | Caduet | Usual Care |
|---|---|---|
| Started | 779 | 682 |
| Eligible for efficacy analysis | 760 | 657 |
| Completed | 686 | 638 |
| Not completed | 93 | 44 |
| Withdrew: Death | 5 | 2 |
| Withdrew: Adverse event | 36 | 0 |
| Withdrew: Lost to follow-up | 12 | 19 |
| Withdrew: Other | 6 | 7 |
| Withdrew: Withdrawal by subject | 34 | 16 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).
| percent risk | Caduet | Usual Care |
|---|---|---|
| Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12 | 12.5 ± 8.26 | 16.3 ± 10.51 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).
| percent risk | Caduet | Usual Care |
|---|---|---|
| Framingham 10-year Risk of Total CHD at Month 4 | 12.5 ± 7.96 | 16.3 ± 10.80 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).
| percent risk | Caduet | Usual Care |
|---|---|---|
| European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12 | 3.0 ± 2.89 | 3.7 ± 3.69 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).
| percent risk | Caduet | Usual Care |
|---|---|---|
| European SCORE 10-year Risk of Fatal CVD at Month 4 | 3.1 ± 3.13 | 3.7 ± 3.69 |
Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).
| percent risk | Caduet | Usual Care |
|---|---|---|
| Framingham 10-year Risk of Stroke at Month 12 | 3.7 ± 2.25 | 4.9 ± 2.87 |
Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).
| percent risk | Caduet | Usual Care |
|---|---|---|
| Framingham 10-year Risk of Stroke at Month 4 | 3.7 ± 2.21 | 4.9 ± 2.81 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.
| percent risk | Caduet | Usual Care |
|---|---|---|
| Month 4 | -7.2705 (-7.90 to -6.64) | -2.5155 (-3.19 to -1.84) |
| Month 12 | -7.2374 (-7.87 to -6.61) | -2.5167 (-3.19 to -1.84) |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.
| percent risk | Caduet | Usual Care |
|---|---|---|
| Month 4 | -1.8438 (-2.06 to -1.63) | -0.9678 (-1.20 to -0.74) |
| Month 12 | -1.9693 (-2.16 to -1.77) | -0.9963 (-1.21 to -0.79) |
| mmHg | Caduet | Usual Care |
|---|---|---|
| Systolic | 133.5 ± 14.32 | 134.5 ± 14.96 |
| Diastolic | 80.7 ± 8.74 | 81.1 ± 9.32 |
| mmHg | Caduet | Usual Care |
|---|---|---|
| Systolic | 130.6 ± 13.84 | 134.3 ± 15.21 |
| Diastolic | 79.2 ± 8.39 | 81.1 ± 9.27 |
| mmHG | Caduet | Usual Care |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at Month 4 | -15.3088 (-17.02 to -13.60) | -12.1619 (-14.00 to -10.32) |
| mmHG | Caduet | Usual Care |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4 | -8.3024 (-9.24 to -7.36) | -6.6908 (-7.70 to -5.68) |
| mmHg | Caduet | Usual Care |
|---|---|---|
| Change From Baseline in SBP at Month 12 | -18.2409 (-19.94 to -16.55) | -12.4903 (-14.32 to -10.66) |
| mmHg | Caduet | Usual Care |
|---|---|---|
| Change From Baseline in DBP at Month 12 | -10.0128 (-10.96 to -9.07) | -6.8429 (-7.86 to -5.83) |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
| mg/dL | Caduet | Usual Care |
|---|---|---|
| TC | 156.0 ± 34.14 | 195.2 ± 37.03 |
| LDL | 80.9 ± 28.47 | 116.4 ± 32.47 |
| HDL | 47.6 ± 13.93 | 46.8 ± 13.49 |
| Triglycerides | 143.5 ± 83.26 | 164.8 ± 95.74 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
| mg/dL | Caduet | Usual Care |
|---|---|---|
| TC | 163.3 ± 38.42 | 196.6 ± 36.36 |
| LDL | 87.1 ± 32.40 | 117.3 ± 31.57 |
| HDL | 47.3 ± 13.48 | 47.1 ± 13.61 |
| Triglycerides | 151.5 ± 98.61 | 166.4 ± 98.53 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.
| mg/dL | Caduet | Usual Care |
|---|---|---|
| TC | -42.7542 (-46.35 to -39.15) | -3.8144 (-7.75 to 0.12) |
| LDL | -38.2765 (-41.52 to -35.03) | -2.9628 (-6.50 to 0.58) |
| HDL | -0.2060 (-1.07 to 0.65) | -1.1978 (-2.13 to -0.26) |
| Triglycerides | -20.5645 (-27.30 to -13.83) | 3.0828 (-4.26 to 10.43) |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
| mg/dL | Caduet | Usual Care |
|---|---|---|
| TC | -37.1024 (-40.52 to -33.69) | -4.0368 (-7.71 to -0.36) |
| LDL | -33.2420 (-36.17 to -30.32) | -3.4168 (-6.58 to -0.25) |
| HDL | -0.4339 (-1.41 to 0.54) | -1.0105 (-2.06 to 0.04) |
| Triglycerides | -15.2270 (-23.12 to -7.33) | 3.0398 (-5.51 to 11.59) |
Goals set at \<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \<140/90 mm Hg or \<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.
| percentage of participants | Caduet | Usual Care |
|---|---|---|
| JNC Month 4 | 65.2 | 62.6 |
| JNC Month 12 | 76.1 | 60.6 |
| ESC Month 4 | 48.6 | 46.0 |
| ESC Month 12 | 58.2 | 47.5 |
Goal set at \<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \<80 mg/dL according to the European (EU) Society of Cardiology guidelines.
| Percentage of participants | Caduet | Usual Care |
|---|---|---|
| US Month 4 | 77.3 | 28.2 |
| US Month 12 | 71.9 | 28.8 |
| EU Month 4 | 52.4 | 13.3 |
| EU Month 12 | 46.7 | 11.5 |
Treatments indicative of prescribed medications other than study provided Caduet.
| participants | Caduet | Usual Care |
|---|---|---|
| Month 4: anti-hypertensive and/or lipid lowering | 648 | 642 |
| Month 4: anti-hypertensive | 647 | 637 |
| Month 4: lipid lowering | 45 | 202 |
| Month 4: anti-hypertensive and lipid lowering | 44 | 197 |
| Month 12: anti-hypertensive and/or lipid lowering | 655 | 642 |
| Month 12: anti-hypertensive | 654 | 638 |
| Month 12: lipid lowering | 46 | 208 |
| Month 12: anti-hypertensive and lipid lowering | 45 | 204 |
Treatments indicative of prescribed medications other than study provided Caduet.
| Participants | Caduet | Usual Care |
|---|---|---|
| Increased dose | 30 | 90 |
| increased dose of anti-hypertensive medications | 30 | 88 |
| increased dose of lipid lowering medications | 0 | 2 |
| increase in either medication | 4 | 45 |
| increase in both medications | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Caduet | — | 51/779 (6.5%) | 356/779 (45.7%) |
| Usual Care | — | 22/682 (3.2%) | 289/682 (42.4%) |
| Event | Caduet | Usual Care |
|---|---|---|
| Urinary tract infectionInfections and infestations | 3/779 | 0/682 |
| Acute myocardial infarctionCardiac disorders | 2/779 | 2/682 |
| Myocardial ischaemiaCardiac disorders | 0/779 | 2/682 |
| Myocardial infarctionCardiac disorders | 2/779 | 0/682 |
| Chest painGeneral disorders | 2/779 | 0/682 |
| AppendicitisInfections and infestations | 2/779 | 1/682 |
| PneumoniaInfections and infestations | 2/779 | 0/682 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/779 | 0/682 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/779 | 0/682 |
| Ischaemic strokeNervous system disorders | 2/779 | 0/682 |
| Event | Caduet | Usual Care |
|---|---|---|
| Oedema peripheralGeneral disorders | 52/779 | 11/682 |
| HeadacheNervous system disorders | 23/779 | 15/682 |
| NasopharyngitisInfections and infestations | 22/779 | 10/682 |
| BronchitisInfections and infestations | 12/779 | 15/682 |
| DizzinessNervous system disorders | 17/779 | 9/682 |
| Chest painGeneral disorders | 16/779 | 10/682 |
| Upper respiratory tract infectionInfections and infestations | 16/779 | 14/682 |
| Blood triglycerides increasedInvestigations | 11/779 | 14/682 |
| Blood creatine phosphokinase increasedInvestigations | 15/779 | 5/682 |
| PharyngitisInfections and infestations | 6/779 | 13/682 |
| Age, Customized(participants) | Caduet as Assigned | Usual Care as Assigned | Total |
|---|---|---|---|
| < 18 years | 0 | 0 | 0 |
| 18 to 44 years | 58 | 55 | 113 |
| 45 to 64 years | 450 | 361 | 811 |
| > = 65 years | 275 | 262 | 537 |
| Sex: Female, Male(Participants) | Caduet as Assigned | Usual Care as Assigned | Total |
|---|---|---|---|
| Female | 368 | 334 | 702 |
| Male | 415 | 344 | 759 |
Showing the first 100 of 126 sites across 20 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →